{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T03:19:58Z","timestamp":1787887198372,"version":"build-2784847793"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.breast.2026.104763","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T08:17:10Z","timestamp":1774599430000},"page":"104763","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Optimizing axillary lymph node management in early-stage HR+\/HER2- breast cancer: Practical strategies for enhanced detection rates"],"prefix":"10.1016","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8800-8044","authenticated-orcid":false,"given":"Marc","family":"Thill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Jo\u00e3o","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Criscitiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Kurzeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Pruneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Riedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Angel","family":"Garc\u00eda-S\u00e1enz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Mattar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Srock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Emde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Coersmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gnant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.breast.2026.104763_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.breast.2026.104763_bib2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1055\/a-2238-3199","article-title":"Identification of patients with early HR+ HER2- breast cancer at high risk of recurrence","volume":"84","author":"Fasching","year":"2024","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"7","key":"10.1016\/j.breast.2026.104763_bib3","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41416-024-02580-3","article-title":"Rethinking surgical revisions: impact of the MonarchE trial on axillary dissection in hormone-positive HER2-negative early breast cancer patients potentially eligible for abemaciclib","volume":"130","author":"Gallard","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2026.104763_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103674","article-title":"Breast cancer highlights from 2023: knowledge to guide practice and future research","author":"Cardoso","year":"2024","journal-title":"Breast"},{"issue":"13","key":"10.1016\/j.breast.2026.104763_bib5","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJMoa2313487","article-title":"Omitting axillary dissection in breast cancer with sentinel-node metastases","volume":"390","author":"de Boniface","year":"2024","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.breast.2026.104763_bib6","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1200\/JCO.22.01565","article-title":"Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year results of the randomized controlled EORTC 10981-22023 AMAROS Trial","volume":"41","author":"Bartels","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104763_bib7","series-title":"NCCN Clinical Practice Guidelines in oncology (NCCN guidelines\u00ae): breast cancer","year":"2024"},{"issue":"2","key":"10.1016\/j.breast.2026.104763_bib8","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104763_bib9","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1056\/NEJMoa2412063","article-title":"Axillary surgery in breast cancer \u2014 primary results of the INSEMA Trial","volume":"392","author":"Reimer","year":"2025","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.breast.2026.104763_bib10","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1200\/JCO-25-00099","article-title":"Sentinel lymph Node biopsy in Early-Stage Breast Cancer: ASCO Guideline update","volume":"43","author":"Park","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104763_bib11","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.3390\/cancers14081898","article-title":"Definition of high-risk early hormone-positive HER2 negative breast cancer: a consensus review","volume":"14","author":"Garutti","year":"2022","journal-title":"Cancers"},{"issue":"21","key":"10.1016\/j.breast.2026.104763_bib12","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.2217\/fon-2022-0310","article-title":"A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer","volume":"18","author":"Sheffield","year":"2022","journal-title":"Future Oncol"},{"issue":"19","key":"10.1016\/j.breast.2026.104763_bib13","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104763_bib14","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2026.104763_bib15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10549-023-07002-1","volume":"201","author":"Martin","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104763_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1340764","article-title":"Therapeutic evolution in HR+\/HER2- breast cancer: from targeted therapy to endocrine therapy","volume":"15","author":"Cao","year":"2024","journal-title":"Front Pharmacol"},{"issue":"Suppl 10","key":"10.1016\/j.breast.2026.104763_bib17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12919-021-00224-5","article-title":"Optimizing treatment selection, and sequencing decisions for Management of HR-Positive, HER2-Negative advanced breast cancer \u2013 proceedings from breast cancer expert group meeting","volume":"15","author":"Dawood","year":"2021","journal-title":"BMC Proc"},{"key":"10.1016\/j.breast.2026.104763_bib18","unstructured":"Verzenio (abemaciclib). Prescribing information. Revised February 2025 https:\/\/uspl.lilly.com\/verzenio\/verzenio.html#pi [accessed 29 June 2025].."},{"key":"10.1016\/j.breast.2026.104763_bib19","unstructured":"Verzenio (abemaciclib). Summary of product characteristics. Updated 7 March 2025 https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/verzenios-epar-product-information_en.pdf [accessed 29 June 2025].."},{"key":"10.1016\/j.breast.2026.104763_bib20","unstructured":"Kisqali (ribociclib). Summary of product characteristics. Updated 24 April 2025 https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kisqali-epar-product-information_en.pdf [accessed 29 June 2025].."},{"key":"10.1016\/j.breast.2026.104763_bib21","unstructured":"Ibrance (palbociclib). Summary of product characteristics. Updated 3 June 2025 https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ibrance-epar-product-information_en.pdf [accessed 29 June 2025].."},{"key":"10.1016\/j.breast.2026.104763_bib22","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1200\/JCO.20.03639","article-title":"Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer-the Penelope-B trial","volume":"39","author":"Loibl","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104763_bib23","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.21.02554","article-title":"Adjuvant palbociclib for early breast cancer: the PALLAS Trial results (ABCSG-42\/AFT-05\/BIG-14-03)","volume":"40","author":"Gnant","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.breast.2026.104763_bib24","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1200\/JCO.2025.43.16_suppl.515","article-title":"Dalpiciclib (Dalp) plus endocrine therapy (ET) as adjuvant treatment for HR+\/HER2\u2013 early breast cancer (BC): the randomized, phase 3, DAWNA-A trial. Abstract 515","volume":"43","author":"Shao","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104763_bib25","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamaoncol.2022.1488","article-title":"Treatment with adjuvant abemaciclib plus endocrine therapy in patients with high-risk early breast cancer who received neoadjuvant chemotherapy","volume":"8","author":"Martin","year":"2022","journal-title":"JAMA Oncol"},{"issue":"34","key":"10.1016\/j.breast.2026.104763_bib26","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104763_bib27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.breast.2026.104763_bib28","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.23.01994","volume":"42","author":"Rastogi","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.breast.2026.104763_bib29","doi-asserted-by":"crossref","first-page":"vi552","DOI":"10.1093\/annonc\/mdw435.02","article-title":"Breast cancer, early stage interim results from neoMONARCH: a neoadjuvant phase II study of abemaciclib in postmenopausal women with HR +\/HER2- breast cancer (BC)","volume":"27","author":"Hurvitz","year":"2016","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1016\/j.breast.2026.104763_bib30","volume":"40","author":"Cobb","year":"2022","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.breast.2026.104763_bib31","article-title":"Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC)","volume":"42","author":"Loi","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104763_bib32","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41523-022-00482-2","article-title":"Abemaciclib in combination with pembrolizumab for HR+, HER2\u2212 metastatic breast cancer: phase 1b study","volume":"8","author":"Rugo","year":"2022","journal-title":"npj Breast Cancer"},{"issue":"3","key":"10.1016\/j.breast.2026.104763_bib33","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000538596","article-title":"Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie recommendations for the diagnosis and treatment of patients with early breast cancer: update 2024","volume":"19","author":"Park-Simon","year":"2024","journal-title":"Breast Care"},{"key":"10.1016\/j.breast.2026.104763_bib34","unstructured":"AGO guidelines. Breast cancer surgery oncological aspects. https:\/\/www.ago-online.de\/fileadmin\/ago-online\/downloads\/_leitlinien\/kommission_mamma\/2024\/englisch\/Einzeldateien\/AGO_2024E_08_Breast_Cancer_Surgery_-_Oncological_Aspects.pdf [accessed 3 March 2025].."},{"key":"10.1016\/j.breast.2026.104763_bib35","doi-asserted-by":"crossref","DOI":"10.1159\/000546080","article-title":"St. Gallen\/Vienna 2025 summary of key messages on therapy in early breast cancer from the 2025 St. Gallen International Breast Cancer Conference (SGBCC)","author":"Ditsch","year":"2025","journal-title":"Breast Care"},{"key":"10.1016\/j.breast.2026.104763_bib36","series-title":"EUSOMA Guidelines for breast cancer management","year":"2020"},{"key":"10.1016\/j.breast.2026.104763_bib39","series-title":"ESMO-MCBS scorecards","year":"2023"},{"issue":"S3","key":"10.1016\/j.breast.2026.104763_bib40","volume":"33","author":"Ruf","year":"2022","journal-title":"Annals of Oncoloy"},{"key":"10.1016\/j.breast.2026.104763_bib41","unstructured":"Verzenio (abemaciclib). US prescribing information. Updated October 2021 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/208716s006s007s008lbl.pdf [accessed 16 January 2026].."},{"key":"10.1016\/j.breast.2026.104763_bib42","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/sj.bjc.6605769","article-title":"Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy","volume":"103","author":"Tanioka","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2026.104763_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2020.109468","article-title":"Diagnostic accuracy of axillary staging by ultrasound in early breast cancer patients","volume":"135","author":"Riedel","year":"2021","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.breast.2026.104763_bib44","first-page":"1","volume":"5","author":"Sood","year":"2019","journal-title":"J Global Oncol"},{"key":"10.1016\/j.breast.2026.104763_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104453","article-title":"CADONOT: comparing axillary dissection or not in breast cancer surgery","volume":"81","author":"Mattar","year":"2025","journal-title":"Breast"},{"issue":"3","key":"10.1016\/j.breast.2026.104763_bib46","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/SLA.0000000000001863","article-title":"Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized Trial","volume":"266","author":"Giuliano","year":"2017","journal-title":"Ann Surg"},{"issue":"S3","key":"10.1016\/j.breast.2026.104763_bib47","first-page":"120P","volume":"33","author":"Ruf","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104763_bib48","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1245\/s10434-023-14404-4","article-title":"Impact of imaging-guided localization on performance of tailored axillary surgery in patients with clinically node-positive breast cancer: prospective cohort study within TAXIS (OPBC-03, SAKK 23\/16, IBCSG 57-18, ABCSG-53, GBG 101)","volume":"31","author":"Weber","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"10.1016\/j.breast.2026.104763_bib49","doi-asserted-by":"crossref","first-page":"e375","DOI":"10.1016\/S1470-2045(20)30084-X","article-title":"Knowledge gaps in oncoplastic breast surgery","volume":"21","author":"Weber","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.breast.2026.104763_bib50","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1001\/jamasurg.2014.1086","article-title":"Selective surgical localization of axillary lymph nodes containing metastases in patients with breast cancer: a prospective feasibility trial","volume":"150","author":"Caudle","year":"2015","journal-title":"JAMA Surg"},{"issue":"10","key":"10.1016\/j.breast.2026.104763_bib51","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","article-title":"Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection","volume":"34","author":"Caudle","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.breast.2026.104763_bib52","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1097\/SLA.0000000000004572","article-title":"Prospective, multicenter registry study to evaluate the clinical feasibility of targeted axillary dissection (TAD) in node-positive breast cancer patients","volume":"276","author":"Kummel","year":"2022","journal-title":"Ann Surg"},{"issue":"7","key":"10.1016\/j.breast.2026.104763_bib53","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.3390\/cancers13071539","article-title":"The evolving role of marked lymph node biopsy (MLNB) and targeted axillary dissection (TAD) after neoadjuvant chemotherapy (NACT) for node-positive breast cancer: systematic review and pooled analysis","volume":"13","author":"Swarnkar","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.breast.2026.104763_bib54","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.3390\/cancers13071565","volume":"13","author":"Banys-Paluchowski","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.breast.2026.104763_bib55","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12885-019-5292-2","article-title":"Does the number of removed axillary lymph nodes in high-risk breast cancer patients influence the survival?","volume":"19","author":"Ebner","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.breast.2026.104763_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinsp.2023.100207","article-title":"The effectiveness of ultrasound-guided core needle biopsy in detecting lymph node metastases in the axilla in patients with breast cancer: systematic review and meta-analysis","volume":"78","author":"Xu","year":"2023","journal-title":"Clinics"},{"issue":"1","key":"10.1016\/j.breast.2026.104763_bib57","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.rxeng.2021.07.004","article-title":"Preoperative axillary ultrasonography in patients with breast cancer: a prospective study to evaluate its ability to predict axillary tumor load","volume":"64","author":"Vallejos","year":"2022","journal-title":"Radiologia (Engl Ed)"},{"issue":"2","key":"10.1016\/j.breast.2026.104763_bib58","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40265-024-02144-y","article-title":"Efficacy and Safety of CDK4\/6 Inhibitors: a focus on HR+\/HER2- early breast cancer","volume":"85","author":"Klocker","year":"2025","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.breast.2026.104763_bib59","doi-asserted-by":"crossref","first-page":"7741","DOI":"10.1038\/s41598-020-63637-w","article-title":"Primary breast cancer and health related quality of life in Spanish women: the EpiGEICAM case-control study","volume":"10","author":"Fern\u00e1ndez de Larrea-Baz","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.breast.2026.104763_bib60","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1186\/s12905-023-02543-5","article-title":"The relation between obesity and breast cancer risk in women by considering menstruation status and geographical variations: a systematic review and meta-analysis","volume":"23","author":"Dehesh","year":"2023","journal-title":"BMC Womens Health"},{"issue":"5","key":"10.1016\/j.breast.2026.104763_bib61","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11912-019-0787-1","article-title":"The impact of obesity on breast cancer diagnosis and treatment","volume":"21","author":"Lee","year":"2019","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"10.1016\/j.breast.2026.104763_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2025.01.002","article-title":"Dynamics of molecular heterogeneity in high-risk luminal breast cancer-from intrinsic to adaptive subtyping","volume":"43","author":"Denkert","year":"2025","journal-title":"Cancer Cell"},{"issue":"14","key":"10.1016\/j.breast.2026.104763_bib63","doi-asserted-by":"crossref","first-page":"7843","DOI":"10.3390\/ijms23147843","article-title":"Applications of circulating tumor cells and circulating tumor DNA in precision oncology for breast cancers","volume":"23","author":"Addanki","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.breast.2026.104763_bib64","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12967-023-04841-w","article-title":"Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway","volume":"22","author":"Tufail","year":"2024","journal-title":"J Transl Med"},{"issue":"4","key":"10.1016\/j.breast.2026.104763_bib65","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(13)70035-4","article-title":"International Breast Cancer Study Group Trial 23-01 investigators. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial","volume":"14","author":"Galimberti","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2026.104763_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102085","article-title":"The Lucerne Toolbox 2 to optimise axillary management for early breast cancer: a multidisciplinary expert consensus","volume":"61","author":"Kaidar-Person","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"6","key":"10.1016\/j.breast.2026.104763_bib67","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa012782","article-title":"A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer","volume":"349","author":"Veronesi","year":"2003","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.breast.2026.104763_bib68","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/annonc\/mdn746","article-title":"Sentinel node biopsy compared with complete axillary dissection for staging early breast cancer with clinically negative lymph nodes: results of randomized trial","volume":"20","author":"Canavese","year":"2009","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.breast.2026.104763_bib69","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/jnci\/djj158","article-title":"Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial","volume":"98","author":"Mansel","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.breast.2026.104763_bib70","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1470-2045(10)70207-2","article-title":"Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial","volume":"11","author":"Krag","year":"2010","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104763_bib71","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1245\/s10434-012-2569-y","article-title":"Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048\/13\/2000","volume":"20","author":"Sola","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.breast.2026.104763_bib72","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ejso.2016.12.011","article-title":"Eight-year follow up result of the OTOASOR trial: the optimal treatment of the axilla - surgery or radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: a randomized, single centre, phase III, non-inferiority trial","volume":"43","author":"Salvolt","year":"2017","journal-title":"Eur J Surg Oncol"},{"issue":"9","key":"10.1016\/j.breast.2026.104763_bib73","doi-asserted-by":"crossref","first-page":"5732","DOI":"10.1245\/s10434-022-11866-w","article-title":"Preservation of axillary lymph nodes compared with complete dissection in T1-2 breast cancer patients presenting one or two metastatic sentinel lymph nodes: the SINODAR-ONE multicenter randomized clinical trial","volume":"29","author":"Tinterri","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.breast.2026.104763_bib74","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1186\/s12885-017-3443-x","article-title":"Clinically node negative breast cancer patients undergoing breast conserving therapy, sentinel lymph node procedure versus follow-up: a Dutch randomized controlled multicentre trial (BOOG 2013-08)","volume":"17","author":"Van Roozendaal","year":"2017","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.breast.2026.104763_bib75","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.20892\/j.issn.2095-3941.2022.0085","article-title":"Feasibility of sentinel lymph node biopsy omission after integration of 18F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial","volume":"19","author":"Li","year":"2022","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.breast.2026.104763_bib76","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12885-022-09273-1","article-title":"No axillary surgical treatment for lymph node-negative patients after ultra-sonography [NAUTILUS]: protocol of a prospective randomized clinical trial","volume":"22","author":"Jung","year":"2022","journal-title":"BMC Cancer"},{"issue":"19","key":"10.1016\/j.breast.2026.104763_bib77","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1200\/JCO.2012.45.2615","article-title":"Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343","volume":"31","author":"Hughes","year":"2013","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.breast.2026.104763_bib78","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jama.2013.278932","article-title":"Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial","volume":"310","author":"Boughey","year":"2013","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.breast.2026.104763_bib79","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","article-title":"Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study","volume":"14","author":"Kuehn","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2026.104763_bib80","series-title":"RF2-03: diagnostic performance of axillary ultrasound after neoadjuvant chemotherapy in initially node-positive breast cancer patients \u2013 results from the prospective AXSANA registry trial","author":"Hartmann","year":"2025"},{"key":"10.1016\/j.breast.2026.104763_bib81","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1184021","article-title":"Axillary lymph node dissection versus radiotherapy in breast cancer with positive sentinel nodes after neoadjuvant therapy (ADARNAT trial)","volume":"13","author":"Garcia-Tejedor","year":"2023","journal-title":"Front Oncol"},{"issue":"17","key":"10.1016\/j.breast.2026.104763_bib82","article-title":"Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+\/HER2- early breast cancer: primary results from the phase III NATALEE trial","volume":"41","author":"Slamon","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104763_bib83","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.breast.2026.104763_bib84","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-Gene assay to inform chemotherapy benefit in node-positive breast cancer","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104763_bib85","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/1745-6215-14-261","volume":"14","author":"Hofmann","year":"2013","journal-title":"Trials"},{"issue":"15","key":"10.1016\/j.breast.2026.104763_bib86","article-title":"Prognostic impact of recurrence score, endocrine response and clinical-pathological factors in high-risk luminal breast cancer: results from the WSG-ADAPT HR+\/HER2- chemotherapy trial","volume":"39","author":"Gluz","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000731?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000731?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T09:59:38Z","timestamp":1778925578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626000731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":84,"alternative-id":["S0960977626000731"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104763","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing axillary lymph node management in early-stage HR+\/HER2- breast cancer: Practical strategies for enhanced detection rates","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104763","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104763"}}